In conclusion, the current study shows that the complex landscape of BRAF mutated colorectal cancer with or without concomitant PIK3CA mutations offers several leads for therapeutic targeting to improve outcomes of this subset of metastatic cancer patients associated with adverse survival. This evidence concerns the gene BRAF and metastatic malignant neoplasm.